J & J Commits up to US$1 B for Protagonist’s Preclinical Crohn’s Disease Drug
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 6 (Table of Contents)
Published: 15 Jun-2017
DOI: 10.3833/pdr.v2017.i6.2257 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Johnson and Johnson (J&J) subsidiary, Janssen Biotech, has licensed global rights to the preclinical Crohn’s disease (CD) drug candidate, PTG-200, from Protagonist Therapeutics in a deal potentially worth nearly US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS